Clock.bio - About the company
Clock.bio is a seed company based in Cambridge (United Kingdom), founded in 2020 by and . It operates as a Developer of treatments for age-related diseases using human pluripotent stem cells. Clock.bio has raised $5.3M in funding from LocalGlobe. The company has 242 active competitors, including 62 funded and 76 that have exited. Its top competitors include companies like Revance Therapeutics, Beam Therapeutics and Intellia Therapeutics.
Company Details
Developer of treatments for age-related diseases using human pluripotent stem cells. This company harnesses the regenerative capabilities of these cells to identify and develop novel therapies. They utilize a unique aging model to force-age induced pluripotent stem cells (iPSCs), triggering their self-rejuvenation mechanism. Unbiased CRISPR screens then identify genes crucial for cell rejuvenation, enabling a comprehensive understanding of rejuvenation biology and the creation of new treatment approaches. The technology allows for rapid decoding of human rejuvenation biology, accelerating the development of effective therapies.
- Website
- Email ID
- @clock.bio
- Registered Address
- PIONEER HOUSE VISION PARK,HISTON,CAMBRIDGE,CAMBRIDGESHIRE,UNITED KINGDOM,CB24 9NL
Key Metrics
Founded Year
2020
Location
Cambridge, United Kingdom
Stage
Seed
Total Funding
in 1 round
Latest Funding Round
Investors
Ranked
48th among
Similar Companies
Legal entities associated with Clock.bio
Clock.bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CIN: 12909273 United Kingdom, Deadpooled | Sep 27, 2020 | - | - |
Get your free copy of Clock.bio's company profile
Clock.bio's funding and investors
Clock.bio has raised a total funding of $5.3M over 1 round. Its latest funding round was a Seed round on Oct 09, 2024 for $5.3M. 4 investors participated in its latest round, lead by LocalGlobe.
Clock.bio has 3 institutional investors including LocalGlobe, BlueYard and Onsight Ventures. Jonathan Milner is only Angel Investor in Clock.bio.
Here is the list of recent funding rounds of Clock.bio:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Oct 09, 2024 | $5.3M | Seed | 2287212 | 8553285 | LocalGlobe, BlueYard, and |
Access funding benchmarks and valuations. Sign up today!View details of Clock.bio's funding rounds and investors
Clock.bio's founders and board of directors
The founders of Clock.bio are and . is the CEO of Clock.bio.
Here are the details of Clock.bio's key team members:
- : Co-Founder of Clock.bio.
- : Co-Founder of Clock.bio.
- : CEO of Clock.bio.
View details of
Access 秘密研究所 on any website
Our Google Chrome extension lets you view company details while browsing their websites
Clock.bio's Competitors and alternates
Top competitors of Clock.bio include Revance Therapeutics, Beam Therapeutics and Intellia Therapeutics. Here is the list of Top 10 competitors of Clock.bio, ranked by 秘密研究所 score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | 秘密研究所 Score |
|---|---|---|---|---|---|
1st | Revance Therapeutics 2002, Newark (United States), Acquired | Developer of neurotoxin aesthetic and therapeutic products for skin treatments | $155M | 72/100 | |
2nd |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | BB Biotech, HTIF听&补尘辫;听 | 69/100 |
3rd | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases | $85M | 68/100 | |
4th | _1557388532154.png?height=40&width=40){kind=logo} Verve 2018, Cambridge (United States), Acquired | Developer of gene-editing therapies for treating coronary artery disease | $216M | Rock Springs Capital, HTIF听&补尘辫;听 | 66/100 |
5th | _1591332761406.jpg?height=40&width=40){kind=logo} Editas Medicine 2013, Cambridge (United States), Public | Developer of therapeutics for rare genetic diseases | $210M | Foresite Capital, Omega Funds听&补尘辫;听 | 63/100 |
6th | Orthofix 1980, Lewisville (United States), Public | Developer of reconstructive and regenerative solutions for bone-related conditions | - | - | 61/100 |
7th |  Ensoma 2019, Boston (United States), Series B | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | $205M | 5AM Ventures, Takeda Ventures听&补尘辫;听 | 60/100 |
8th | Avita Medical 1992, Cambridge (United Kingdom), Public | Regenerative and Respiratory Medicine product company | - | Orbimed, NorthStar Impact听&补尘辫;听 | 59/100 |
9th |  Hugel 2001, Chuncheon-si (South Korea), Acquired | Developer of therapeutics in the field of aesthetics | - | DAOL Investment, Mubadala听&补尘辫;听 | 59/100 |
10th | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | Hercules Capital, 听&补尘辫;听 | 58/100 |
48th | 2020, Cambridge (United Kingdom), Seed | Developer of treatments for age-related diseases using human pluripotent stem cells | $5.3M | LocalGlobe, BlueYard听&补尘辫;听 | 39/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Clock.bio's competitors? Click to see the top ones
Clock.bio's Investments and acquisitions
Clock.bio has made no investments or acquisitions yet.
Reports related to Clock.bio
Here is the latest report on Clock.bio's sector:
View
News related to Clock.bio
Media has covered Clock.bio for 1 event in last 1 year.
鈥�
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Clock.bio
Explore our recently published companies
- dAIgnostiX - Bengaluru based, 2018 founded, Unfunded company
- Globe Teleservices - Singapore based, 2012 founded, Unfunded company
- ActionPoint - Bucharest based, 2021 founded, Public company
